If you have ever wondered whether “the little red pill” or its cousins could help with low arousal, lubrication, or orgasm, you are not alone. Phosphodiesterase‑5 inhibitors (PDE5 inhibitors) like sildenafil and tadalafil are well‑studied in men, but their use in women is far less clear.
Some clinics and online platforms now offer these medications to women off‑label for sexual concerns. Before you consider that route, it helps to understand what the research actually shows, where the evidence is mixed, and what questions to ask.
How do sildenafil and tadalafil work?
Both sildenafil and tadalafil are PDE5 inhibitors. They work by blocking the PDE5 enzyme, which helps relax smooth muscle and increase blood flow in certain tissues.
In men, that primarily means increased blood flow to the penis, improving the ability to get and maintain an erection in response to sexual stimulation.
In women, PDE5 is also present in genital tissues, and these drugs can increase clitoral and vaginal blood flow and genital engorgement.
On a physiological level, studies show that PDE5 inhibitors can enhance genital vasocongestion (blood flow) in women. The bigger question has been: does that translate into better subjective arousal, desire, and satisfaction?
What’s been studied in women so far?
Sildenafil: most data in SSRI‑related dysfunction and arousal disorders
One landmark randomized controlled trial in JAMA looked at sildenafil in premenopausal women with sexual dysfunction caused by SSRI antidepressant treatment. Compared with placebo, women taking sildenafil had:
Higher global ratings of sexual function
Improvements in arousal and orgasm domains on validated questionnaires
Subsequent trials and open‑label studies have suggested sildenafil may help some women with sexual arousal disorder (with normal desire) by improving subjective arousal and orgasm, particularly in specific subgroups.
However, results across studies are mixed:
Some randomized trials report modest benefits on arousal/orgasm scores.
Others show no significant advantage over placebo for broad female sexual dysfunction.
Side effects in women are similar to those in men: headache, flushing, nasal congestion, and sometimes visual changes.
Tadalafil: small, targeted studies
Evidence for tadalafil in women is more limited but growing. A prospective 12‑week study in premenopausal women with type 1 diabetes and genital arousal disorder found that daily tadalafil 5 mg:
Improved subjective genital arousal and orgasm
Increased sexual enjoyment and satisfaction with the frequency of sexual activity
Enhanced quality of life scores
The authors concluded that tadalafil “seems to improve subjective sexual aspects and could be used to treat genital arousal disorder” in this specific group, but they also noted major limitations: small sample size and no placebo control.
Other trials are ongoing, including randomized placebo‑controlled studies of tadalafil for female sexual dysfunction in particular populations (for example, circumcised women or women with vascular contributors).
What does the broader evidence say about PDE5 inhibitors in women?
A 2023 meta‑analysis that pooled data from 13 randomized controlled trials (1,605 women) found that PDE5 inhibitors as a class were associated with:
Improved orgasm satisfaction
Increased sexual arousal
Higher overall sexual satisfaction compared with placebo
However, the same analysis also found increased rates of headache and flushing with PDE5 inhibitors.
A conceptual review of all published studies noted an important nuance:
PDE5 drugs reliably improve physiological genital response (blood flow, lubrication, engorgement).
But women’s sexual experiences depend more heavily on psychological, relational, and contextual factors, so improved blood flow does not always equal better subjective desire or satisfaction.
The authors concluded that the lack of consistent, robust efficacy in women is likely due to this mismatch between physiological and psychological components of sexual response, and that pharmacology alone is rarely enough.
What’s on‑label vs. off‑label?
In men, sildenafil and tadalafil are on‑label, FDA‑approved for erectile dysfunction.
In women, neither sildenafil nor tadalafil is currently FDA‑approved for sexual dysfunction. Their use is considered off‑label.
Off‑label prescribing is legal and common in medicine, but it relies on clinician judgment, smaller or mixed studies, and case‑by‑case risk‑benefit discussions rather than large, definitive approval trials.
Currently, the only centrally acting medication approved specifically for low sexual desire in some women is bremelanotide (PT‑141) for premenopausal women with HSDD; even there, careful patient selection and counseling are needed.
When might sildenafil or tadalafil be considered for women?
Based on existing data and expert reviews, PDE5 inhibitors may be considered in select women with:
Primarily genital arousal difficulties (lubrication, engorgement, orgasm) rather than low desire alone
Clear vascular or medication‑related contributors (for example, diabetes with vascular complications, SSRI‑associated sexual dysfunction)
Adequate relationship safety and communication, where psychological and relational factors are being addressed in parallel
Even in these situations, expectations should be realistic: improvements may be modest and may not cover every aspect of sexual wellbeing.
They are generally not first‑line when low desire is primarily related to stress, mood, trauma, relationship conflict, or mismatched desire between partners, where therapy and whole‑person approaches are usually more appropriate.
Key safety and “buyer beware” points
If you see sildenafil or tadalafil marketed directly to women online, keep a few things in mind:
These medications can interact with nitrates, certain heart medications, and some blood pressure drugs, and are not safe for everyone.
Headache, flushing, dizziness, and indigestion are the most common side effects; rare but serious cardiovascular events are a concern in high‑risk patients.
Doses and formulations should be individualized; more is not always more.
Claims of “universal female Viagra” are not supported by the current evidence.
Because women’s sexual concerns are often multi‑factorial (physical, hormonal, emotional, relational), any medication should be considered as one tool, not the whole toolkit.
What to ask your clinician
If you are curious about whether sildenafil or tadalafil might make sense for you, consider asking:
What is the main issue: desire, arousal, lubrication, orgasm, pain, or something else?
Have we fully considered hormonal factors, medications, mental health, and relationship context?
Is there evidence that PDE5 inhibitors help in people with my specific profile (for example, diabetes, SSRI use, vascular issues)?
What benefits could I realistically expect, and what are the risks and side effects for me personally?
How will we monitor whether it is helping, and what is the plan if it does not?
A good sexual wellness plan for women typically blends education, lifestyle support, mental health care when needed, relationship work, and targeted medical treatment rather than relying on a single pill.
Sildenafil and tadalafil can improve genital blood flow in women and show promise in certain specific conditions, but they are still off‑label, with mixed results and a need for much more research—especially outside tightly defined study groups. The safest path is a conversation with a clinician who understands women’s sexual health and can help you weigh these options within a broader, whole‑person approach.
